Risk of Hospitalization in Synucleinopathies and Impact of Psychosis

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2023 Oct 9

PMID 37810618

Authors

Capucine Piat

Aidan F Mullan

Cole D Stang

Mania Hajeb

Emanuele Camerucci

Pierpaolo Turcano

Peter R Martin

James H Bower

Rodolfo Savica

Affiliations

Soon will be listed here.

Abstract

Background: Few studies have investigated the risk of hospitalization among patients with synucleinopathies (Parkinson disease, Dementia with Lewy Bodies, Parkinson disease dementia, Multiple System Atrophy) with associated psychosis and the impact of antipsychotic treatments on hospital admissions and duration of the stay.

Objective: To determine the risk of hospitalization among patients with synucleinopathies and in patients with associated psychosis. To evaluate the impact of antipsychotic treatments on hospital admission of patients with synucleinopathies and psychosis in an incident cohort study in Olmsted County, Minnesota (MN).

Methods: We used the Rochester Epidemiology Project (REP) to define an incident cohort of patients with clinically diagnosed synucleinopathies (1991-2010) in Olmsted County, MN. A movement disorder specialist reviewed all medical records to confirm the clinical diagnosis of synucleinopathies using the NINDS/NIMH unified diagnostic criteria.

Results: We included 416 incident cases of clinically diagnosed synucleinopathies from 2,669 hospitalizations. 409 patients (98.3%) were admitted to the hospital at least once for any cause after the onset of parkinsonism. The median number of hospitalizations for a single patient was 5. In total, 195 (46.9%) patients met the criteria for psychosis: patients with psychosis had a 49% (HR = 1.49, < 0.01) increased risk of hospitalization compared to patients without psychosis. Among patients with psychosis, 76 (39%) received antipsychotic medication. Treatment with antipsychotic medications did not affect the risk of hospitalization (HR = 0.93, = 0.65). The median length of hospitalization among the entire cohort was 1 (IQR 0-4) day. There was no difference between hospitalization length for patients with no psychosis and patients with active psychosis (RR = 1.08, = 0.43) or patients with resolved psychosis (RR = 0.79, = 0.24).

Conclusion: Psychosis increases the risk of hospitalization in patients with clinically defined synucleinopathies; however, it does not affect the length of hospital stays in our cohort. Antipsychotic treatment does not affect the risk of hospitalization in our study.

References

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

Low V, Ben-Shlomo Y, Coward E, Fletcher S, Walker R, Clarke C . Measuring the burden and mortality of hospitalisation in Parkinson's disease: A cross-sectional analysis of the English Hospital Episodes Statistics database 2009-2013. Parkinsonism Relat Disord. 2015; 21(5):449-54. DOI: 10.1016/j.parkreldis.2015.01.017. View

Rajagopalan K, Rashid N, Doshi D . Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries. J Med Econ. 2023; 26(1):769-776. DOI: 10.1080/13696998.2023.2220597. View

Aarsland D, Larsen J, Karlsen K, Lim N, Tandberg E . Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999; 14(10):866-74. View

Woodford H, Walker R . Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord. 2005; 20(9):1104-8. DOI: 10.1002/mds.20485. View

Goetz C, Stebbins G . Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993; 43(11):2227-9. DOI: 10.1212/wnl.43.11.2227. View

Ravina B, Marder K, Fernandez H, Friedman J, McDonald W, Murphy D . Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007; 22(8):1061-8. DOI: 10.1002/mds.21382. View

Stang C, Mullan A, Camerucci E, Hajeb M, Turcano P, Martin P . Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010). J Parkinsons Dis. 2022; 12(4):1319-1327. PMC: 9336204. DOI: 10.3233/JPD-213035. View

Peterson B, Rocca W, Bower J, Savica R, Mielke M . Identifying incident Parkinson's disease using administrative diagnostic codes: a validation study. Clin Park Relat Disord. 2021; 3. PMC: 8218579. DOI: 10.1016/j.prdoa.2020.100061. View

10.

Ahlskog J . Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls. Mayo Clin Proc. 2014; 89(7):997-1003. DOI: 10.1016/j.mayocp.2014.02.018. View

11.

Turcano P, Mielke M, Josephs K, Bower J, Parisi J, Boeve B . Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010. Mov Disord. 2017; 32(10):1439-1446. PMC: 5931206. DOI: 10.1002/mds.27125. View

12.

Wetmore J, Li S, Yan H, Irfan M, Rashid N, Peng Y . Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: Retrospective cohort study. Parkinsonism Relat Disord. 2019; 68:95-101. DOI: 10.1016/j.parkreldis.2019.10.018. View

13.

Okunoye O, Horsfall L, Marston L, Walters K, Schrag A . Rate of Hospitalizations and Underlying Reasons Among People with Parkinson's Disease: Population-Based Cohort Study in UK Primary Care. J Parkinsons Dis. 2021; 12(1):411-420. PMC: 7612266. DOI: 10.3233/JPD-212874. View

14.

Gilman S, Wenning G, Low P, Brooks D, Mathias C, Trojanowski J . Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9):670-6. PMC: 2676993. DOI: 10.1212/01.wnl.0000324625.00404.15. View

15.

St Sauver J, Grossardt B, Yawn B, Melton 3rd L, Rocca W . Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol. 2011; 173(9):1059-68. PMC: 3105274. DOI: 10.1093/aje/kwq482. View

16.

Savica R, Grossardt B, Bower J, Ahlskog J, Rocca W . Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol. 2013; 70(7):859-66. PMC: 3707980. DOI: 10.1001/jamaneurol.2013.114. View

17.

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

18.

Forsaa E, Larsen J, Wentzel-Larsen T, Goetz C, Stebbins G, Aarsland D . A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010; 67(8):996-1001. DOI: 10.1001/archneurol.2010.166. View

19.

Badwal K, Kiliaki S, Dugani S, Pagali S . Psychosis Management in Lewy Body Dementia: A Comprehensive Clinical Approach. J Geriatr Psychiatry Neurol. 2021; 35(3):255-261. DOI: 10.1177/0891988720988916. View

20.

Santos Garcia D, de Deus Fonticoba T, Cores C, Suarez Castro E, Hernandez Vara J, Jesus S . Falls Predict Acute Hospitalization in Parkinson's Disease. J Parkinsons Dis. 2021; 13(1):105-124. PMC: 9912731. DOI: 10.3233/JPD-212539. View